<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="11426" end="11430" sStart="11188" offset="238" sid="null" wn="1" wnkey="use%2:34:01::" text="Because the synovium is an important contributor to pathogenesis in arthritis, primary cultures of HSFs were used as target cells, and concentrations of PGE 2 in media conditioned by the HSFs were used as a measure of IL-1? stimulation." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="11426" end="11430" sStart="null" offset="238" sid="null" wn="1" wnkey="use%2:34:01::" text="Because the synovium is an important contributor to pathogenesis in arthritis, primary cultures of HSFs were used as target cells, and concentrations of PGE 2 in media conditioned by the HSFs were used as a measure of IL-1? stimulation." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="11426" end="11430" sStart="null" offset="238" sid="null" wn="1" wnkey="use%2:34:01::" text="Because the synovium is an important contributor to pathogenesis in arthritis, primary cultures of HSFs were used as target cells, and concentrations of PGE 2 in media conditioned by the HSFs were used as a measure of IL-1? stimulation." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="11426" end="11430" sStart="null" offset="238" sid="null" wn="1" wnkey="use%2:34:01::" text="Because the synovium is an important contributor to pathogenesis in arthritis, primary cultures of HSFs were used as target cells, and concentrations of PGE 2 in media conditioned by the HSFs were used as a measure of IL-1? stimulation." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="26087" end="26098" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" text="Indeed, IL-1Ra gene therapy has demonstrated impressive efficacy in animal models of RA and OA, and a phase I human trial has recently confirmed that the human IL-1Ra cDNA can be safely &lt;b&gt;transferred&lt;/b&gt; to and expressed within human rheumatoid joints [ 19 ] . A planned phase II study will determine the efficacy of this procedure." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="25547" end="25554" sStart="null" offset="0" sid="null" wn="2" wnkey="success%1:04:00::" text="Gene delivery may offer the greatest chance of early &lt;b&gt;success&lt;/b&gt;." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="25547" end="25554" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="Gene delivery may offer the greatest chance of early &lt;b&gt;success&lt;/b&gt;." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="1394" end="1400" sStart="null" offset="150" sid="r11.strong.j.0829" wn="1" wnkey="strong%3:00:00::" text="According to the literature [ 4 5 6 ] it is necessary to maintain an IL-1Ra : IL-1 molar ratio of 10-100 or more to achieve a strong inhibitory effect." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/ar795.anc" start="18961" end="18966" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" text="As &lt;b&gt;shown&lt;/b&gt; in Fig." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/ar795.anc" start="18961" end="18966" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" text="As &lt;b&gt;shown&lt;/b&gt; in Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="1981" end="1987" sStart="null" offset="207" sid="r8.number.n.0805" wn="1" wnkey="number%1:07:00::" text="Moreover, it is theoretically possible to regulate levels of IL-1Ra gene expression in a manner commensurate with disease activity [ 8 ] . IL-1Ra gene therapy has been evaluated in a number of different animal models of RA and OA, with extremely promising results [ 9 10 11 12 13 14 15 16 17 18 ] . Indeed, a phase I human study of IL-1Ra gene therapy in RA [ 19 ] was recently successfully completed." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="8848" end="8854" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Adherent cells were transduced with an amphotropic retrovirus, DFG-hIL-1?-neo, which encodes the &lt;b&gt;mature&lt;/b&gt; form of human IL-1? fused to the leader sequence of human parathyroid hormone to enable efficient secretion, and neomycin phosphotransferase [ 21 ] . Retroviral transductants were positively selected in complete DMEM containing Geneticin at 0.5 mg/ml." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="18930" end="18936" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="To establish a situation of chronic IL-1? stimulation as might be encountered in an arthritic joint, experiments were designed like that described for Figure 4, but in this case the source of IL-1? was provided by the addition of dermal fibroblasts genetically modified to constitutively secrete &lt;b&gt;mature&lt;/b&gt; human IL-1?." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="8848" end="8854" sStart="null" offset="0" sid="null" wn="" wnkey="null" text="Adherent cells were transduced with an amphotropic retrovirus, DFG-hIL-1?-neo, which encodes the &lt;b&gt;mature&lt;/b&gt; form of human IL-1? fused to the leader sequence of human parathyroid hormone to enable efficient secretion, and neomycin phosphotransferase [ 21 ] . Retroviral transductants were positively selected in complete DMEM containing Geneticin at 0.5 mg/ml." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="18930" end="18936" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="To establish a situation of chronic IL-1? stimulation as might be encountered in an arthritic joint, experiments were designed like that described for Figure 4, but in this case the source of IL-1? was provided by the addition of dermal fibroblasts genetically modified to constitutively secrete &lt;b&gt;mature&lt;/b&gt; human IL-1?." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="8848" end="8854" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Adherent cells were transduced with an amphotropic retrovirus, DFG-hIL-1?-neo, which encodes the &lt;b&gt;mature&lt;/b&gt; form of human IL-1? fused to the leader sequence of human parathyroid hormone to enable efficient secretion, and neomycin phosphotransferase [ 21 ] . Retroviral transductants were positively selected in complete DMEM containing Geneticin at 0.5 mg/ml." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="18930" end="18936" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="To establish a situation of chronic IL-1? stimulation as might be encountered in an arthritic joint, experiments were designed like that described for Figure 4, but in this case the source of IL-1? was provided by the addition of dermal fibroblasts genetically modified to constitutively secrete &lt;b&gt;mature&lt;/b&gt; human IL-1?." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="18930" end="18936" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="To establish a situation of chronic IL-1? stimulation as might be encountered in an arthritic joint, experiments were designed like that described for Figure 4, but in this case the source of IL-1? was provided by the addition of dermal fibroblasts genetically modified to constitutively secrete &lt;b&gt;mature&lt;/b&gt; human IL-1?." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="8848" end="8854" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Adherent cells were transduced with an amphotropic retrovirus, DFG-hIL-1?-neo, which encodes the &lt;b&gt;mature&lt;/b&gt; form of human IL-1? fused to the leader sequence of human parathyroid hormone to enable efficient secretion, and neomycin phosphotransferase [ 21 ] . Retroviral transductants were positively selected in complete DMEM containing Geneticin at 0.5 mg/ml." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="18930" end="18936" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="To establish a situation of chronic IL-1? stimulation as might be encountered in an arthritic joint, experiments were designed like that described for Figure 4, but in this case the source of IL-1? was provided by the addition of dermal fibroblasts genetically modified to constitutively secrete &lt;b&gt;mature&lt;/b&gt; human IL-1?." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="8848" end="8854" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Adherent cells were transduced with an amphotropic retrovirus, DFG-hIL-1?-neo, which encodes the &lt;b&gt;mature&lt;/b&gt; form of human IL-1? fused to the leader sequence of human parathyroid hormone to enable efficient secretion, and neomycin phosphotransferase [ 21 ] . Retroviral transductants were positively selected in complete DMEM containing Geneticin at 0.5 mg/ml." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="8848" end="8854" sStart="null" offset="0" sid="null" wn="" wnkey="null" text="Adherent cells were transduced with an amphotropic retrovirus, DFG-hIL-1?-neo, which encodes the &lt;b&gt;mature&lt;/b&gt; form of human IL-1? fused to the leader sequence of human parathyroid hormone to enable efficient secretion, and neomycin phosphotransferase [ 21 ] . Retroviral transductants were positively selected in complete DMEM containing Geneticin at 0.5 mg/ml." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="18930" end="18936" sStart="null" offset="0" sid="null" wn="" wnkey="null" text="To establish a situation of chronic IL-1? stimulation as might be encountered in an arthritic joint, experiments were designed like that described for Figure 4, but in this case the source of IL-1? was provided by the addition of dermal fibroblasts genetically modified to constitutively secrete &lt;b&gt;mature&lt;/b&gt; human IL-1?." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="19233" end="19237" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" text="Even at the highest dose, the steady dilution of rIL-1Ra in the presence of constant IL-1? synthesis rapidly &lt;b&gt;lost&lt;/b&gt; its protective effects." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="1833" end="1839" sStart="null" offset="59" sid="r9.level.n.0408" wn="2" wnkey="level%1:26:01::" text="Moreover, it is theoretically possible to regulate levels of IL-1Ra gene expression in a manner commensurate with disease activity [ 8 ] . IL-1Ra gene therapy has been evaluated in a number of different animal models of RA and OA, with extremely promising results [ 9 10 11 12 13 14 15 16 17 18 ] . Indeed, a phase I human study of IL-1Ra gene therapy in RA [ 19 ] was recently successfully completed." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="23275" end="23281" sStart="null" offset="145" sid="r9.level.n.0942" wn="1" wnkey="level%1:07:00::" text="In the face of continual dilution, the constitutive production of the IL-1Ra gene product was able to maintain effective protein levels and was able to sustain and increase protection of the HSFs from IL-1 stimulation as time progressed." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="16769" end="16773" sStart="null" offset="217" sid="r10.high.j.0413" wn="1" wnkey="high%3:00:02::" text="At the low and medium doses rIL-1Ra had little protective effect but, relative to the 24 hour time point, a significant increase in IL-1 stimulation was seen in the wells receiving the high dose by day 4. In the wells receiving the HIG-82-IL-1Ra +cells, protection from IL-1 stimulation was maintained over time." />
    <s path="[OANC]/data/written_2/technical/biomed/ar795.anc" start="23137" end="23141" sStart="null" offset="7" sid="r7.1.face.n.0861" wn="2147483647" wnkey="null" text="In the face of continual dilution, the constitutive production of the IL-1Ra gene product was able to maintain effective protein levels and was able to sustain and increase protection of the HSFs from IL-1 stimulation as time progressed." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/ar795.anc" start="21031" end="21039" sStart="null" offset="0" sid="null" wn="1" wnkey="exercise%2:34:00::" text="Furthermore, and in agreement with earlier literature on this subject [ 4 5 27 ] , both forms of IL-1Ra required a molar excess over IL-1 of at least two orders of magnitude to &lt;b&gt;exercise&lt;/b&gt; an inhibition of 100%." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/ar795.anc" start="21031" end="21039" sStart="null" offset="0" sid="null" wn="2" wnkey="exercise%2:41:00::" text="Furthermore, and in agreement with earlier literature on this subject [ 4 5 27 ] , both forms of IL-1Ra required a molar excess over IL-1 of at least two orders of magnitude to &lt;b&gt;exercise&lt;/b&gt; an inhibition of 100%." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/ar795.anc" start="21031" end="21039" sStart="null" offset="0" sid="null" wn="1" wnkey="exercise%2:34:00::" text="Furthermore, and in agreement with earlier literature on this subject [ 4 5 27 ] , both forms of IL-1Ra required a molar excess over IL-1 of at least two orders of magnitude to &lt;b&gt;exercise&lt;/b&gt; an inhibition of 100%." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="25531" end="25537" sStart="null" offset="0" sid="null" wn="1" wnkey="chance%1:26:00::" text="Gene delivery may offer the greatest &lt;b&gt;chance&lt;/b&gt; of early success." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="25531" end="25537" sStart="null" offset="0" sid="null" wn="4 1" wnkey="null" text="Gene delivery may offer the greatest &lt;b&gt;chance&lt;/b&gt; of early success." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="21569" end="21574" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" text="In experiments in which IL-1? was &lt;b&gt;added&lt;/b&gt; at the same time as the source of IL-1Ra, similar end-point concentrations of IL-1Ra were found to provide corresponding inhibitory effects, despite the fact that the recombinant protein was at its maximal concentration at the time of IL-1 stimulation whereas that from the modified cells was zero." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar795.anc" start="13084" end="13090" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" text="By &lt;b&gt;adding&lt;/b&gt; the recombinant protein and the modified cells at the same time as IL-1?, the concentration of rIL-1Ra would be at its maximum at the time of initial IL-1? stimulation." />
  </sentences>
</list>